{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:58:27Z","timestamp":1785243507637,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04144-0","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:20:17Z","timestamp":1765012817000},"page":"2135-2142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world incidence and risk of myelodysplastic syndrome and acute myeloid leukemia secondary to PARP inhibitors in ovarian cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9258-5927","authenticated-orcid":false,"given":"Javier","family":"Coraz\u00f3n Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gonz\u00e1lez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Arenaza Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-9787","authenticated-orcid":false,"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Casado Herraez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"S\u00e1nchez-del Hoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"4144_CR1","unstructured":"European Cancer Information System (ECIS). https:\/\/ecis.jrc.ec.europa.eu\/. Accessed January 2025."},{"key":"4144_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed January 2025."},{"issue":"1","key":"4144_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"key":"4144_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103685","author":"C Valenza","year":"2024","unstructured":"Valenza C, Mongillo M, Gigli F, Trapani D, Katrini J, Nicol\u00f2 E, et al. Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms. ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103685.","journal-title":"ESMO Open"},{"issue":"23","key":"4144_CR5","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","volume":"28","author":"V Marmouset","year":"2022","unstructured":"Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, et al. Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience. Clin Cancer Res. 2022;28(23):5211\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1622.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4144_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/uro3010006","volume":"3","author":"I Kourampi","year":"2023","unstructured":"Kourampi I, Tsetzan IP, Kappi P, Jain N. PARP inhibitors in the management of BRCA-positive prostate cancer: an overview. Uro. 2023;3(1):40\u20137. https:\/\/doi.org\/10.3390\/uro3010006.","journal-title":"Uro"},{"issue":"24","key":"4144_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246385","volume":"13","author":"CM Csizmar","year":"2021","unstructured":"Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. PARP inhibitors and myeloid neoplasms: a double-edged sword. Cancers (Basel). 2021;13(24):6385. https:\/\/doi.org\/10.3390\/cancers13246385.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4144_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41(3):609\u201317. https:\/\/doi.org\/10.1200\/JCO.22.01549.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4144_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005.","journal-title":"Ann Oncol"},{"issue":"5","key":"4144_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4144_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241.","journal-title":"Ann Oncol"},{"key":"4144_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ygyno.2023.06.508","volume":"176","author":"U Matulonis","year":"2023","unstructured":"Matulonis U, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, et al. Final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6). Gynecol Oncol. 2023;176:31\u20132.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4144_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"PM Morice","year":"2021","unstructured":"Morice PM, Leary A, Dolladille C, Chr\u00e9tien B, Poulain L, Gonz\u00e1lez-Mart\u00edn A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):122\u201334. https:\/\/doi.org\/10.1016\/S2352-3026(20)30360-4.","journal-title":"Lancet Haematol"},{"issue":"3","key":"4144_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","volume":"161","author":"R Nitecki","year":"2021","unstructured":"Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, et al. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials. Gynecol Oncol. 2021;161(3):653\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.011.","journal-title":"Gynecol Oncol"},{"key":"4144_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.912256","volume":"13","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L, et al. Myelodysplastic syndrome\/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data. Front Pharmacol. 2022;13:912256.","journal-title":"Front Pharmacol"},{"issue":"7","key":"4144_CR16","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04144-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04144-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04144-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:11Z","timestamp":1779204731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04144-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4144"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04144-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Ethical approval was granted by the Research Ethics Committee of Hospital Cl\u00ednico San Carlos (Madrid,Spain).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Given the retrospective nature of the study, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Supporting data are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Please contact the corresponding author for any request for any study materials including codes.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}